Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,414 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Executive summary of the Japan Osteoporosis Society Guide for the Use of Bone Turnover Markers in the Diagnosis and Treatment of Osteoporosis (2018 Edition).
Nishizawa Y, Miura M, Ichimura S, Inaba M, Imanishi Y, Shiraki M, Takada J, Chaki O, Hagino H, Fukunaga M, Fujiwara S, Miki T, Yoshimura N, Ohta H; from the Japan Osteoporosis Society Bone Turnover Marker Investigation Committee. Nishizawa Y, et al. Among authors: ohta h. Clin Chim Acta. 2019 Nov;498:101-107. doi: 10.1016/j.cca.2019.08.012. Epub 2019 Aug 16. Clin Chim Acta. 2019. PMID: 31425674 Free article. Review.
Guidelines for the use of biochemical markers of bone turnover in osteoporosis (2004).
Nishizawa Y, Nakamura T, Ohta H, Kushida K, Gorai I, Shiraki M, Fukunaga M, Hosoi T, Miki T, Chaki O, Ichimura S, Nakatsuka K, Miura M; Committee on the Guidelines for the Use of Biochemical Markers of Bone Turnover in Osteoporosis Japan Osteoporosis Society. Nishizawa Y, et al. Among authors: ohta h. J Bone Miner Metab. 2005;23(2):97-104. doi: 10.1007/s00774-004-0547-6. J Bone Miner Metab. 2005. PMID: 15750686 No abstract available.
Design of a pragmatic approach to evaluate the effectiveness of concurrent treatment for the prevention of osteoporotic fractures: rationale, aims and organization of a Japanese Osteoporosis Intervention Trial (JOINT) initiated by the Research Group of Adequate Treatment of Osteoporosis (A-TOP).
Shiraki M, Kuroda T, Miyakawa N, Fujinawa N, Tanzawa K, Ishizuka A, Tanaka S, Tanaka Y, Hosoi T, Itoi E, Morimoto S, Itabashi A, Sugimoto T, Yamashita T, Gorai I, Mori S, Kishimoto H, Mizunuma H, Endo N, Nishizawa Y, Takaoka K, Ohashi Y, Ohta H, Fukunaga M, Nakamura T, Orimo H. Shiraki M, et al. Among authors: ohta h. J Bone Miner Metab. 2011 Jan;29(1):37-43. doi: 10.1007/s00774-010-0188-x. Epub 2010 May 13. J Bone Miner Metab. 2011. PMID: 20461422 Clinical Trial.
Diagnostic criteria for primary osteoporosis: year 2012 revision.
Soen S, Fukunaga M, Sugimoto T, Sone T, Fujiwara S, Endo N, Gorai I, Shiraki M, Hagino H, Hosoi T, Ohta H, Yoneda T, Tomomitsu T; Japanese Society for Bone and Mineral Research and Japan Osteoporosis Society Joint Review Committee for the Revision of the Diagnostic Criteria for Primary Osteoporosis. Soen S, et al. Among authors: ohta h. J Bone Miner Metab. 2013 May;31(3):247-57. doi: 10.1007/s00774-013-0447-8. Epub 2013 Apr 4. J Bone Miner Metab. 2013. PMID: 23553500
Comparison of concurrent treatment with vitamin K2 and risedronate compared with treatment with risedronate alone in patients with osteoporosis: Japanese Osteoporosis Intervention Trial-03.
Tanaka S, Miyazaki T, Uemura Y, Miyakawa N, Gorai I, Nakamura T, Fukunaga M, Ohashi Y, Ohta H, Mori S, Hagino H, Hosoi T, Sugimoto T, Itoi E, Orimo H, Shiraki M. Tanaka S, et al. Among authors: ohta h. J Bone Miner Metab. 2017 Jul;35(4):385-395. doi: 10.1007/s00774-016-0768-5. Epub 2016 Aug 2. J Bone Miner Metab. 2017. PMID: 27484436 Clinical Trial.
Randomized head-to-head comparison of minodronic acid and raloxifene for fracture incidence in postmenopausal Japanese women: the Japanese Osteoporosis Intervention Trial (JOINT)-04.
Uemura Y, Sone T, Tanaka S, Miyazaki T, Tsukiyama M, Taguchi A, Soen S, Mori S, Hagino H, Sugimoto T, Fukunaga M, Ohta H, Nakamura T, Orimo H, Shiraki M; Adequate Treatment of Osteoporosis (A-TOP) Research Group. Uemura Y, et al. Among authors: ohta h. Curr Med Res Opin. 2020 Nov;36(11):1847-1859. doi: 10.1080/03007995.2020.1816537. Epub 2020 Sep 14. Curr Med Res Opin. 2020. PMID: 32870712 Clinical Trial.
Influence of symptomatic periodontal disease on changes in skeletal bone density during medication therapy for osteoporosis in postmenopausal women: the Japanese Osteoporosis Intervention Trial (JOINT)-04 and JOINT-05.
Taguchi A, Uemura Y, Tanaka S, Ohta H, Mori S, Hagino H, Shiraki M, Nakamura T, Soen S; Adequate Treatment of Osteoporosis (A-TOP) research group. Taguchi A, et al. Among authors: ohta h. Arch Osteoporos. 2021 Dec 27;17(1):7. doi: 10.1007/s11657-021-01054-w. Arch Osteoporos. 2021. PMID: 34958402 Clinical Trial.
[A-TOP research group/JOINT-02].
Kuroda T, Ohta H, Shiraki M, Miyakawa N, Hosoi T, Nakamura T, Fukunaga M, Orimo H. Kuroda T, et al. Among authors: ohta h. Nihon Rinsho. 2007 Nov 28;65 Suppl 9:271-4. Nihon Rinsho. 2007. PMID: 18161118 Review. Japanese. No abstract available.
2,414 results